Organization
Sandoz, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Sandoz, Inc.
... in a margin of 31.3% of net sales, in line with prior year.Sandoz net sales were USD 2.5 billion (+4%, -4% cc) in the first ...
... Novartis International AG / Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics ...
... incredibly excited by our recent acquisition of a portfolio of ANDAs from Sandoz. We saw an opportunity to acquire medicines already approved in the U.S. ...
... A patent fight has already delayed Sandoz' biosimilar version of Amgen's anti-inflammatory blockbuster Enbrel. And now, it looks as ...
... and Mark Vineis, Vice President of Managed Markets & Specialty Services at Sandoz Inc United States," said Sheila Arquette, Executive Director of NASP. "Kelly Ratliff ...
... incredibly excited by our recent acquisition of a portfolio of ANDAs from Sandoz. We saw an opportunity to acquire medicines already approved in the U.S. ...
... incredibly excited by our recent acquisition of a portfolio of ANDAs from Sandoz. We saw an opportunity to acquire medicines already approved in the U.S. ...
... Holzkirchen, Germany - Sandoz, a Novartis division and the global leader in biosimilars, announced today that ...
... Table of Contents and Figures:https://www.futuremarketinsights.com/reports/sample/rep-gb-6466 For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights ...
... favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. The District Court held that Amphastar is 'the prevailing party' in ...
... to join its rivals in the ovarian cancer maintenance setting. - Novartis’ Sandoz, which pioneered biosimilars in the U.S., is at it again. This time ...
... Novartis International AG / Sandoz receives positive CHMP opinion for proposed biosimilar infliximab . Processed and transmitted ...
... favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. The District Court held that Amphastar is "the prevailing party" in ...
... details were provided, but a Tilray spokesperson told the Financial Post that Sandoz has not taken a financial stake in the company. In an email, ...
... produced by Anacor Pharmacueticals, Inc., the drug is now a product of Sandoz, a division of Novartis. Service provider: My Express Care Pharmacy, plus Braun ...
... 13th, 2018, Momenta Pharma (MNTA) announced that the US FDA has approved Sandoz's Abbreviated New Drug Application for Glatopa (glatiramer acetate injection) 40 mg/mL, and ...
... President and Chief Executive Officer of Momenta Pharmaceuticals. Wheeler continued, 'Operationally, with Sandoz's launch of Glatopa 40 mg we should gain more clarity on this ...
... President and Chief Executive Officer of Momenta Pharmaceuticals. Wheeler continued, "Operationally, with Sandoz's launch of Glatopa 40 mg we should gain more clarity on this ...
... Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa ...
... After last week’s FDA rejection for Sandoz’s generic Advair, Novartis’ copycat arm needed a win. And it got a ...
... Sandoz, a Novartis division, today announced the US FDA approval and launch of ...
... today announced that the U.S. Food and Drug Administration (FDA) has approved Sandoz's Abbreviated New Drug Application for Glatopa (glatiramer acetate injection) 40 mg/mL and ...
... drugmaker now says it’s “highly unlikely” the generic will launch this year. Sandoz’ version is the third to be turned away by the FDA. RELATED: ...
... Ken Ren, Ph.D., CASI's Chief Executive Officer commented, 'The acquisition of the Sandoz ANDAs enhances our strategic focus to build a robust pipeline and commercialize ...
... Teva: Mylan's Copaxone copy has already captured serious share Momenta and Novartis' Sandoz unit already has a 20 mg Glatopa dose on the market, but ...
Subscribe now for full coverage on Sandoz, Inc.
Start My Free Trial